CNC Looks 14.6% Undervalued on GF Value™ as Market Prices in Gro
Centene Corporation (CNC) reaffirmed its 2026 adjusted diluted EPS forecast, expecting it to exceed $4.80, slightly below analyst consensus. The company's P/S ratio is 0.16, below its historical median and industry average, reflecting market skepticism. Its GF Score™ is 72/100, indicating moderate financial health. Insider activity shows no buying and $14.6 million in selling, while institutional sentiment is mixed.
How this was made
The 30-second read
Why it matters
Guidance reaffirmation provides fresh data for valuation models; the valuation discount may attract value‑oriented investors.
Market read
Centene's guidance update is the primary market‑moving event in the article.
What to watch
Potential upside from Medicaid margin improvements and the 14.6% valuation discount noted by GF Value™.
Background
Centene is a large Medicaid managed‑care provider with $33.2 B market cap, facing profitability challenges but showing margin improvement.
Ticker impact
Centene reaffirmed its 2026 adjusted EPS guidance at $4.80, slightly below consensus, and highlighted improved Medicaid pre‑tax margins.
Potential modest downside or flat price action as investors reassess growth outlook.
Guidance is a primary disclosure but the miss is small; market reaction likely limited.
Market effects
Reaffirmed guidance may influence sentiment toward the broader managed‑care sector, especially Medicaid operators.
U.S. healthcare stocks could see modest re‑pricing as investors digest Centene's outlook.
Limited; primarily U.S. market focus.
Counterpoint
The modest EPS miss could be a buying opportunity if the market overreacts to a small guidance gap.
Key entities
- ExecutiveDrew Asher
CFO who highlighted Medicaid pre‑tax margin improvement.
